NASDAQ · Medical - Diagnostics & Research

CSTL (CSTL) Stock

$33.42 -0.06% NASDAQ: CSTL Healthcare

Valuation

MetricValue
Price$33.42
Market Cap$1.02B
P/E Ratio-23.63
P/B Ratio1.26
P/S Ratio1.81
EPS (TTM)$0.00
52-Week High$44.28
52-Week Low$14.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-5.10%
ROA-4.15%
ROCE-9.13%
Gross Margin-12.50%
Operating Margin-12.50%
Net Margin-3.78%
Debt/Equity0.08
Current Ratio5.23

Annual Financials (USD)

Metric20212022202320242025
Revenue$94.0M$137.0M$220.0M$332.0M$344.0M
Operating Profit$-40.0M$-73.0M$-68.0M$9.0M$-43.0M
Net Profit$-31.0M$-67.0M$-57.0M$18.0M$-24.0M
EPS$-1.24$-2.58$-2.14$0.62$-0.83
Op Margin-42.6%-53.2%-30.9%2.6%-12.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$463.0M$447.0M$453.0M$531.0M$579.0M
Total Liabilities$51.0M$48.0M$62.0M$75.0M$108.0M
Cash$330.0M$123.0M$99.0M$120.0M$117.0M
Borrowings$8.0M$13.0M$15.0M$26.0M$37.0M

Latest News

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test PR Newswire · Jul 14, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire · Jul 9, 2026 SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation Exec Edge · Jul 1, 2026 Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down Simply Wall St. · Jun 26, 2026 DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-42.0M$-6.0M$65.0M$64.0M
Investing Cash Flow$-70.0M$-172.0M$-30.0M$-78.0M$-96.0M
Financing Cash Flow$5.0M$2.0M$-2.0M$-6.0M$-9.0M
Net Cash Flow$-80.0M$-207.0M$-24.0M$21.0M$-3.0M
Free Cash Flow$-22.0M$-47.0M$-19.0M$37.0M$28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield0.73%
Quick Ratio6.53
Interest Coverage—
Return 1Y51.67%
Return 3Y60.86%
Return 5Y-64.40%

Ownership

Insiders Held2.73%
Institutions Held92.43%
Institutions Float Held95.03%
Institutional HolderSharesReport Date
Blackrock Inc.2,982,9462026-03-31
RTW Investments LP2,758,3352026-03-31
Principal Financial Group, Inc.1,769,8772026-03-31
Portolan Capital Management, LLC1,350,2832026-03-31
Vanguard Capital Management LLC1,177,5222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMN $33.38 -0.48% 12.36 $1.29B 0.00%
CDNA $49.60 +1.29% 23.29 $2.57B 0.00%
DRIO $7.30 +3.99% -10.51 $53.38M 0.00%
EMBCEmbecta Corp. $5.69 +8.38% 3.33 $337.57M 0.81%
EVH $4.23 -1.17% -0.77 $475.79M 0.00%

About CSTL

CSTL is led by CEO Derek J. Maetzold, employs 784 people, headquartered in US, publicly traded since 2019.

CSTL stock trades at $33.42 with a market capitalization of $1.02B. The stock is valued at a price-to-earnings (P/E) ratio of -23.63, price-to-book of 1.26, price-to-sales of 1.81. Over the past 52 weeks the stock has ranged between $14.59 and $44.28, and currently trades 24.5% below its 52-week high.

On profitability, CSTL generates a return on equity (ROE) of -5.10%, return on capital employed of -9.13%, an operating margin of -12.50%, a net profit margin of -3.78%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides